Asia Pacific Recombinant Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Asia Pacific Recombinant Albumin Market size is expected to reach US$ 180,518.5 Million by 2031 from US$ 80,673.7 Million in 2024. The market is estimated to record a CAGR of 12.2% from 2025 to 2031.

Executive Summary and Asia Pacific Recombinant Albumin Market Analysis:

The Asia Pacific recombinant albumin market is growing significantly, driven by rising healthcare needs and advancements in biotechnology. According to the World Health Organization (WHO), the prevalence of liver diseases in the region has escalated, with over 2 million cases reported in 2022, particularly in countries such as China and India. The National Health Commission of China reported a 12% increase in liver disease-related hospitalizations from 2022 to 2023. In 2024, several new recombinant albumin products were expected to be launched, following approvals from the National Medical Products Administration (NMPA) in China, which had been actively promoting innovative therapies. Additionally, the Australian Therapeutic Goods Administration (TGA) has recently approved new formulations, enhancing the availability of recombinant albumin in Australia. These regulatory advancements, coupled with the increasing adoption of recombinant albumin in critical care and surgical settings, are propelling market growth. The combination of rising disease prevalence, supportive regulatory frameworks, and ongoing product innovations creates a conducive environment for the market to grow.

Asia Pacific Recombinant Albumin Market: Strategic Insights

Asia Pacific Recombinant Albumin Market Segmentation Analysis:

• By Source, the Asia Pacific Recombinant Albumin Market is segmented into Human Recombinant Albumin, Bovine Recombinant Albumin, and Other Sources. The Human Recombinant Albumin segment dominated the market in 2024.
• By Application, the Asia Pacific Recombinant Albumin Market is segmented into Excipient in Biotherapeutics and Vaccines, Cell Culture, Drug Delivery, Diagnostics, and Other Applications. The Excipient in Biotherapeutics and Vaccines segment dominated the market in 2024.
• By End User, the Asia Pacific Recombinant Albumin Market is segmented into Pharmaceutical and Biotechnology Companies, Research Institutes, Hospitals and Diagnostic Laboratories, and Others End Users. The Pharmaceutical and Biotechnology Companies segment dominated the market in 2024.

Asia Pacific Recombinant Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Recombinant Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Asia Pacific Recombinant Albumin Market Outlook

A major opportunity for recombinant albumin lies in replacing plasma-derived human serum albumin (HSA) for therapeutic use, addressing safety and plasma-supply constraints. In China, human albumin demand exceeded 1,000 tons in 2024, with imports accounting for over 69% of total supply, according to the Wuhan Municipal Health Commission. To reduce reliance on plasma imports, the National Medical Products Administration (NMPA) approved the world's first rice-derived recombinant human albumin injection developed by Wuhan Healthgen Biotechnology in July 2025. In India, Shilpa Medicare Ltd. became the first domestic company to complete Phase I clinical trials for recombinant human albumin (20%) in August 2024, with Phase III trials authorized by CDSCO in November 2024. These regulatory milestones mark growing confidence in recombinant technology. With liver cirrhosis and hypoalbuminemia increasing globally, recombinant albumin presents a scalable, pathogen-free therapeutic substitute.

Asia Pacific Recombinant Albumin Market Country Insights

By country, the Asia Pacific Recombinant Albumin Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China held the largest share in 2024.

The recombinant albumin market in China is expanding due to rising healthcare needs and increased prevalence of chronic diseases. In 2022, the World Health Organization reported that liver diseases-including hepatitis and cirrhosis are responsible for approximately 1 million deaths annually in China, underlining the critical need for effective treatments. Additionally, according to the National Health Commission of China, cases of liver cirrhosis were projected to rise by 15% by 2024, increasing demand for therapeutic proteins like recombinant albumin. In response, Chinese pharmaceutical companies are ramping up research and development efforts. New recombinant albumin products are being introduced to the market, such as those developed by Sinopharm, which received approval in 2023 from the National Medical Products Administration. Furthermore, government initiatives to promote biotechnology and biopharmaceuticals have led to favorable regulatory frameworks, facilitating faster approval processes for innovative products, as highlighted in the 2023 report by the Ministry of Industry and Information Technology. This growing emphasis on innovation, combined with an increasing aging population and rising healthcare expenditure, is significantly driving the market growth in China.

Asia Pacific Recombinant Albumin Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc, CSL Ltd, Merck KGaA, Sartorius AG, Akron Biotech, HiMedia Laboratories Pvt Ltd, InVitria, Medxbio Pte Ltd, Lazuline Biotech Private Limited, and Cyagen Biosciences.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Recombinant Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise